Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

Defining high-risk acute lymphoblastic leukaemia

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Submit
Thanks for rating
There has been a problem, please refresh and try again.
Published: 23.01.20
Views: 219
Rating:

Dr Ching-Hon Pui - St Jude's Children's Research Hospital, Memphis, USA

Dr Ching-Hon Pui speaks to ecancer at the 2020 ALL Assembly meeting in Frankfurt about the definition of high-risk acute lymphoblastic leukaemia (ALL).

He explains that high-risk patients cannot be defined based on their immunophenotype, genotype or measuring their early treatment response using minimal residual disease (MRD).

Dr Pui explains that in order to identify these patients, multiple factors such as presenting clinical features, age and germline features.

He discusses the latest research in this area which explore the heterogeneity of the disease and cooperative mutations.

Dr Pui believes that in the next five years, clinicians will be using most of these factors to determine the risk of the patient and therefore the appropriate treatment strategy.

Related videos

follow us

WIN 2020


Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation